H.R. 9102

119th CongressIn committee

BINSA Act

Sponsored by John R. Moolenaar (Republican-MI-2)

Cybersecurity Technology & Innovation Telecommunications & Broadband

Cosponsors

Actions

Roll calls

Amendments

Related bills

Actions

Jun 2, 2026 · Library of Congress

Introduced in House

Jun 2, 2026 · Library of Congress

Introduced in House

Jun 2, 2026 · House floor actions

Referred to the House Committee on Financial Services.

Latest activity

Activity

July 2026

Lobbying reported · Sanofi US Services · Jul 21

Sanofi US Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Sanofi US Services — $920,000

BillsH.R. 1 H.R. 5376 H.R. 6423 H.R. 7174 H.R. 7834 H.R. 8698 H.R. 9102 S. 43 S. 832 S. 864 S. 1339 S. 1542 S. 3131 S. 4504

Lobbying reported · Biotechnology Innovation Organization · Jul 21

Biotechnology Innovation Organization reported 2nd Quarter (Apr 1 - June 30) lobbying for Biotechnology Innovation Organization — $2,360,000

Lobbying reported · Amgen · Jul 20

Amgen reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $2,440,000

Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20

Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000

Lobbying reported · Novartis · Jul 20

Novartis reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $1,410,000

Lobbying reported · Fdd Action · Jul 20

Fdd Action reported 2nd Quarter (Apr 1 - June 30) lobbying for Fdd Action — $240,000

BillsH.Con.Res. 38 H.Con.Res. 40 H.Con.Res. 75 H.Con.Res. 84 H.Con.Res. 86 H.J.Res. 176 H.J.Res. 200 H.R. 36 H.R. 425 H.R. 881 H.R. 1048 H.R. 1422 H.R. 1736 H.R. 1800 H.R. 2158 H.R. 2212 H.R. 2505 H.R. 2658 H.R. 2683 H.R. 3307 H.R. 3447 H.R. 3563 H.R. 4397 H.R. 4505 H.R. 4531 H.R. 4920 H.R. 4930 H.R. 5490 H.R. 5853 H.R. 6058 H.R. 6106 H.R. 6230 H.R. 6322 H.R. 6331 H.R. 6469 H.R. 6624 H.R. 6875 H.R. 6988 H.R. 6996 H.R. 7003 H.R. 7037 H.R. 7126 H.R. 7146 H.R. 7178 H.R. 7184 H.R. 7273 H.R. 7380 H.R. 7540 H.R. 7552 H.R. 7567 H.R. 7622 H.R. 7625 H.R. 7668 H.R. 7924 H.R. 8019 H.R. 8022 H.R. 8036 H.R. 8069 H.R. 8106 H.R. 8168 H.R. 8169 H.R. 8170 H.R. 8177 H.R. 8202 H.R. 8283 H.R. 8284 H.R. 8433 H.R. 8516 H.R. 8558 H.R. 8559 H.R. 8595 H.R. 8649 H.R. 8665 H.R. 8693 H.R. 8700 H.R. 8718 H.R. 8730 H.R. 8787 H.R. 8800 H.R. 8901 H.R. 9020 H.R. 9087 H.R. 9102 H.R. 9129 H.R. 9147 H.R. 9227 H.R. 9232 H.R. 9256 H.R. 9322 H.R. 9366 H.R. 9450 H.R. 9451 H.R. 9495 H.R. 9550 H.R. 9592 H.Res. 564 H.Res. 1246 H.Res. 1379 S. 63 S. 556 S. 933 S. 1296 S. 1473 S. 1705 S. 1744 S. 1889 S. 1962 S. 2132 S. 2293 S. 2677 S. 2904 S. 3050 S. 3172 S. 3181 S. 3249 S. 3360 S. 3404 S. 3452 S. 3496 S. 3519 S. 3855 S. 3900 S. 4192 S. 4219 S. 4281 S. 4296 S. 4379 S. 4380 S. 4392 S. 4423 S. 4424 S. 4429 S. 4443 S. 4446 S. 4456 S. 4525 S. 4544 S. 4565 S. 4570 S. 4600 S. 4665 S. 4711 S. 4723 S. 4784 S. 4826 S. 4835 S. 4853 S.J.Res. 114 S.J.Res. 123 S.J.Res. 163 S.J.Res. 184 S.J.Res. 185 S.Res. 236

Lobbying reported · Pfizer · Jul 20

Pfizer reported 2nd Quarter (Apr 1 - June 30) lobbying for Pfizer — $1,880,000

BillsH.Con.Res. 14 H.R. 1 H.R. 4299 H.R. 4930 H.R. 5178 H.R. 5526 H.R. 7391 H.R. 7837 H.R. 8646 H.R. 9102 H.R. 9260 S. 2658

Lobbying reported · Acadia Pharmaceuticals · Jul 20

Acadia Pharmaceuticals reported 2nd Quarter (Apr 1 - June 30) lobbying for Acadia Pharmaceuticals — $700,000

BillsH.R. 1 H.R. 1262 H.R. 1414 H.R. 1492 H.R. 1509 H.R. 3731 H.R. 6130 H.R. 9102 S. 752 S. 832 S. 932 S. 3267

Lobbying reported · Alston & Bird · Jul 20

Alston & Bird reported 2nd Quarter (Apr 1 - June 30) lobbying for Curie Bio Operations — $130,000

BillsH.R. 9102

Lobbying reported · Cornerstone Government Affairs · Jul 20

Cornerstone Government Affairs reported 2nd Quarter (Apr 1 - June 30) lobbying for Johns Hopkins University — $60,000

BillsH.R. 1 H.R. 1048 H.R. 6248 H.R. 7148 H.R. 9102 H.R. 9390 H.R. 9393 H.R. 9504 S. 854 S. 1296 S. 4027

Lobbying reported · Travere Therapeutics · Jul 20

Travere Therapeutics reported 2nd Quarter (Apr 1 - June 30) lobbying for Travere Therapeutics — $140,000

BillsH.R. 1 H.R. 1262 H.R. 1414 H.R. 1518 H.R. 4709 H.R. 9102 S. 932 S. 1040 S. 2658

Lobbying reported · Tiber Creek Group · Jul 19

Tiber Creek Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Astrazeneca — $80,000

BillsH.R. 9102

Lobbying reported · Glaxosmithkline · Jul 16

Glaxosmithkline reported 2nd Quarter (Apr 1 - June 30) lobbying for Glaxosmithkline — $890,000

You’re all caught up.